Kuvi.ai Launches Private Beta of Agentic Finance OS with Seed Round Led by Moon Pursuit Capital, with Additional Support from Transform Ventures and VirtualBacon
Toronto, Canada, July 29, 2025 (GLOBE NEWSWIRE) — Kuvi.ai , the platform pioneering Agentic Finance, has announced the successful completion of its $700,000 seed round, led by Moon Pursuit Capital, and the expansion of its strategic round, which is now oversubscribed. Recent additions include legendary crypto investor Michael Terpin of Transform Ventures and leading Web3 educator Dennis Liu (aka VirtualBacon).
The announcement follows Kuvi.ai's earlier pre-seed (angel) round, which closed in just four days. With the close of the seed round and the opening of the strategic round, Kuvi.ai's valuation has now doubled from $15 million to $30 million.
The funding supports the private beta launch of Kuvi.ai's Agentic Finance Operating System (AF-OS), the first of its kind next-gen interface that empowers users to design, automate, and deploy complex financial strategies using natural language.
Kuvi.ai replaces the need for centralized exchanges, clunky DeFi dashboards, or opaque robo-advisors, enabling users to act with precision, automation, and control. Kuvi.ai is an AI-driven crypto interface designed to make digital asset transactions as simple as typing a message or saying a few words, delivering text-to-trade functionality that removes the need to navigate multiple dApps, bridging solutions, or complex trading interfaces.
Users can instruct Kuvi.ai to buy, sell, or swap tokens across blockchains, and Kuvi.ai does the rest. Unlike pre-programmed bots or chat wrappers, Kuvi.ai allows users to define their financial intent — e.g., 'Buy $1K in memecoins when sentiment spikes and gas is low, exit when BTC dominance rises' — and executes via our proprietary modular and functional agentic framework.
'Kuvi.ai is building the coordination layer for agentic value transfer,' said co-founder and CEO Dylan Dewdney.
Kuv.ai's private beta, rolling out now to early community, investors, supporters, collaborators, and some OTC desks, introduces smart 'Executables.' These are automations tied to market conditions, cross-chain actions, and real-time data. Early integrations include top Solana-native protocols like Raydium and Jupiter, with Ethereum and Bitcoin native protocols soon to follow.
'This is not just a new product,' added co-founder and CTO Jay Nasr. 'It's a complete rethink of how humans interact with financial systems.'
With private beta underway and TGE tentatively slated for late summer/early fall 2025, Kuvi.ai is set to scale its user base, integrations, and community. As the Agentic Finance movement gains traction, Kuvi.ai is positioned to be the flagship OS in a post-app financial world — empowering everyone to manage and multiply wealth through intent-based interfaces.
Please follow Kuvi.AI X: @kuvilabsTelegram: @kuviai
Discord: https://discord.com/invite/r5Hfpk5BPa
Instagram: https://www.instagram.com/kuviai
About Kuvi.ai
Kuvi.ai is an AI-driven crypto interface designed to make digital asset transactions as simple as typing a message or saying a few words, delivering text-to-trade functionality that removes the need to navigate multiple dApps, bridging solutions, or complex trading interfaces. Users can instruct Kuvi.ai to buy, sell, or swap tokens across blockchains, and Kuvi.ai does the rest.
Kuvi.ai is founded by Dylan Dewdney, a crypto OG active since 2011, along with Jay Nasr, and Maxim Sindall, bringing technical depth and go-to-market execution. Kuvi.ai's momentum is powered by a heavyweight advisory and investor roster that includes Michael Terpin, founder of Transform Ventures and early advisor/investor to hundreds of crypto projects, including Ethereum and Tether; Dennis Liu (VirtualBacon), top-tier crypto educator with 400K+ followers; and Peter Vincer, advisor with institutional and U.S. policy access, joins as Advisor for Government Relations. For more information, please visit https://kuvi.ai.
Media contact: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business of Fashion
a minute ago
- Business of Fashion
Oneskin Announces $20 Million Investment From Prelude Growth Partners
Oneskin, the longevity-focussed skincare brand based in California, has secured a $20 million investment from growth equity firm Prelude Growth Partners, the company announced on Wednesday. Prelude Growth Partners' investment buys out a former investor and will not dilute any other shareholders' equity. 'We were really impressed with Prelude immediately,' said Oneskin chief executive Carolina Reis Oliveira, adding that the firm had reached out with detailed plans and suggestions as to how a partnership could be fruitful. Oneskin was founded in 2021 by four Brazilian scientists and uses a proprietary peptide known as OS-01 which the company claims has unique anti-ageing properties. It offers products for the face, body and hair. Its primary channels are its own e-commerce site and Amazon; Reis Oliveira said more than two-third of its business are generated by subscriptions. Prelude Growth Partners' other beauty investments include the premium skin and body care lines Sol de Janeiro, Summer Fridays and Tower28. Two brands it invested in via the brand incubator The Center have now sold — skincare line Naturium to E.l.f Beauty in 2023, and fragrance maker Phlur to TSG Consumer Partners in July 2025. On Tuesday, it announced it has closed a third fund of $600 million earmarked for high-growth consumer brands. 'We're in a good place financially and have a good cushion in terms of cash,' said Reis Oliveira, adding that it will not need to raise again in the near future and that the funds will go towards a brand refresh, supporting clinical trials and on new hires. Oneskin recently appointed a vice president of growth marketing and a creative director, and will soon recruit a head of brand and chief marketing officer. The brand will continue to weigh up a retail entry for 2027 and invest in product development and marketing. Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.
Yahoo
32 minutes ago
- Yahoo
Gynecological Devices Market Valuation to Reach US$ 20.19 Billion By 2033
Driven by an aging population and a strong shift toward minimally invasive procedures, the market is dominated by surgical devices and robotics. Hospitals and clinics remain primary end-users, investing heavily in advanced technology despite reimbursement pressures. Chicago, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The global gynecological devices market was valued at US$ 10.18 billion in 2024 and is expected to reach US$ 20.19 billion by 2033, growing at a CAGR of 7.90% during the forecast period 2025–2033. The global gynecological devices market is currently navigating a period of profound and accelerated transformation. This is not a gradual evolution but a dynamic surge, creating a landscape rich with opportunity for manufacturers, investors, and healthcare systems worldwide. A confluence of powerful drivers—including an unprecedented influx of venture capital into women's health technology, the escalating prevalence of complex gynecological conditions, and a wave of disruptive technological advancements—is fueling this robust growth. The market is moving beyond incremental improvements toward fundamental shifts in diagnostics and therapeutics. Free Report Sample Available for Immediate Download: An exhaustive analysis of data reveals a compelling, multi-layered narrative of expansion. This in-depth market research report dissects nine critical segments, presenting meticulously researched, data-driven insights that collectively illuminate the immense and multifaceted opportunities materializing across the global gynecological devices market. Key Finding in Gynecological Devices Market Market Forecast (2033) US$ 20.19 billion CAGR 7.90% Largest Region (2024) North America (42%) By Product Surgical Devices (53.0%) By End Users Hospitals & Clinics (65.26%) Top Drivers Rapidly aging female population creates a growing patient base. Government initiatives are increasingly focused on promoting women's health. High adoption of advanced and innovative medical technologies. Top Trends Rising physician preference for minimally invasive surgical techniques. Growing use of robotic-assisted surgery for gynecological procedures. Increased focus on early diagnostics with advanced imaging systems. Top Challenges Strict and lengthy regulatory approval cycles for new devices. Declining national birth rate impacting obstetrics device demand. Stringent reimbursement policies and pressure on healthcare cost containment. Venture Capital Investment Ignites a Firestorm of Femtech and Gynecological Device Innovation The financial landscape for women's health has been transformed by a massive surge of venture capital, directly spurring innovation and growth in the gynecological devices market. Funding for femtech startups has exceeded US$5 billion since 2020, with US$1.2 billion deployed in 2024 alone. Broadening the view to all women's health startups brings the 2024 total to US$2.6 billion, and, including all women-centric conditions, investment in the US and Europe reached nearly US$10.6 billion in 2024. This is a truly global trend. In Europe, €339.4 million was invested across 47 femtech deals in 2024, and European femtechs had already attracted over €334 million in venture capital by March 2025. This capital empowers companies to launch breakthrough products, fueling a new wave of innovation. Recent examples include Future Family securing a US$400 million financing program in April 2025 and ByHeart raising US$72 million the same month for manufacturing expansion. Significant 2025 investments underscore the diversity of innovation: Gesynta Pharma (US$29 million) and Conceivable Life Sciences (US$18 million) are advancing novel treatments, while Delfina (US$17 million), Twentyeight Health (US$10 million), and Teal Health (US$10 million) highlight the growing impact of AI-powered maternal health and accessible care. The funding cascade continues with Kegg (US$6.5 million), Egal (US$4 million), Fizimed (€4 million), Ema (US$3 million), Trellis Health (US$1.8 million), Raaz (US$1 million), Calla Lily (£1 million), Mabel (€600,000), Femble (€350,000), and AuraFem Health (US$200,000). The UNICEF Venture Fund further nurtures innovation, offering up to US$100,000 in equity-free funding for emerging economies, ensuring support at every level. Addressing Uterine Fibroids Creates a Significant and Highly Costly Market Opportunity Uterine fibroids represent a highly prevalent and economically significant condition, creating a vast and sustained demand for effective therapeutic solutions within the gynecological devices market. The sheer scale of this public health issue is immense. As of 2024, the estimated annual economic cost of uterine fibroids in the United States has escalated to an astonishing US$41.4 billion. A major component of this economic burden is productivity loss, with an estimated US$17.2 billion lost annually in the U.S. due to missed work and short-term disability. The patient population itself is expanding, with data showing that the number of women in the U.S. diagnosed with uterine fibroids increased by 10.6% between 2010 and 2022. This steady growth signals a consistently expanding patient base requiring treatment. The high out-of-pocket cost of traditional surgical interventions further amplifies the market need for innovative, less invasive, and more cost-effective devices. Without insurance coverage, a myomectomy procedure can cost between US$11,000 and US$22,000, while a full hysterectomy ranges from US$9,600 to US$24,000. Alternative, device-centric treatments also carry substantial price tags, with uterine artery embolization costing between US$10,000 and US$15,000, and radiofrequency ablation ranging from US$8,900 to US$20,000. These costs exhibit significant geographic variability; for instance, a laparoscopic hysterectomy could cost approximately US$28,000 in Cleveland, Ohio, while the same procedure in Atlanta, Georgia, might be closer to US$19,000. This cost-prohibitive environment creates a powerful incentive for the adoption of new technologies in the gynecological devices market that can offer superior outcomes at a lower total cost of care. Assisted Reproductive Technology Forges a Burgeoning and Profitable Niche Device Market The increasing societal demand for fertility assistance, driven by trends such as delayed parenthood and rising infertility rates, is a potent force shaping a specialized and highly profitable segment of the gynecological devices market. The global demand for these services is immense, with approximately 2.5 million In-Vitro Fertilization (IVF) cycles now being performed annually across the world. This trend is particularly pronounced in the United States, where the number of IVF cycles performed in SART (Society for Assisted Reproductive Technology) member clinics surged from 389,993 in 2022 to 432,641 in 2023. These procedures directly resulted in the birth of 95,860 babies in the U.S. in 2023. Comprehensive data from 2021 shows that 238,126 patients in the U.S. initiated a total of 413,776 ART cycles, demonstrating the high volume of procedures. The financial investment from patients is substantial and directly fuels demand for the sophisticated equipment, consumables, and diagnostic tools used in these delicate procedures. The average cost of a single IVF cycle in the U.S. ranges from US$12,000 to US$17,000, with some reports from the Department of Health and Human Services placing the potential cost between US$15,000 and US$20,000. This sustained, high-value patient expenditure ensures a robust and growing revenue stream for manufacturers of the specialized instruments essential to modern fertility treatment, making it a cornerstone of the modern gynecological devices market. Robotic Surgery Revolutionizes Gynecological Procedures and Propels Advanced System Device Adoption Minimally invasive robotic surgery has become the gold standard for many gynecological procedures, offering greater precision, shorter recovery times, and improved patient outcomes. This shift is driving rapid adoption of advanced robotic surgical systems, with the da Vinci system leading the market. In 2024 alone, 2,683,000 procedures were performed globally using da Vinci systems, reflecting exponential usage growth. Hardware sales surged as well, with 493 da Vinci surgical systems placed in healthcare facilities in Q4 2024, bringing full-year placements to 1,526. This expansion resulted in substantial financial gains: Intuitive Surgical reported US$2.41 billion in revenue for Q4 2024, up 25% from the previous year. Recurring revenue in the gynecological devices market from proprietary instruments and accessories climbed to US$1.41 billion in Q4, while capital sales of the systems hit US$1.97 billion for the full year. The da Vinci system generally sells for US$0.7 million to US$3.1 million, signifying significant capital commitment from hospitals. By 2020, over 5,500 da Vinci systems were installed in U.S. hospitals, with more than 2,000 hospitals nationwide now utilizing robotic surgery systems. This robust infrastructure supports continued growth: the global gynecological surgery robot market reached approximately US$3.2 billion in 2024 and is poised for further expansion. The outlook is especially strong given that nearly 600,000 hysterectomies are performed in the U.S. every year, many ideal for robotic assistance. Rising Prevalence of Pelvic and Endometrial Disorders Spurs Urgent Device Innovation A growing awareness among both patients and clinicians regarding the diagnosis and treatment of widespread yet historically underdiagnosed conditions such as endometriosis and pelvic organ prolapse (POP) is opening new frontiers for the gynecological devices market. The addressable patient population is substantial and expanding. Projections indicate that the number of American women suffering from at least one pelvic floor disorder is set to increase to 43.8 million by the year 2050. More specifically, the number of women with POP in the U.S. is expected to climb to 4.9 million by 2050, while the global population of POP patients is projected to reach an enormous 156 million by 2036. For endometriosis, a condition infamous for its diagnostic challenges, the average time from symptom onset to a definitive diagnosis is currently a staggering 8 years and 10 months. This diagnostic delay represents a critical unmet need and a clear opportunity for innovative diagnostic devices. Promising clinical research is underway to address these therapeutic gaps. A clinical trial involving 36 participants is evaluating a cannabidiol extract for endometriosis pain and is expected to conclude in December 2024, while another larger pain reduction trial with 102 participants is set to conclude in August 2024. Success in these trials could pave the way for new treatment paradigms supported by new devices. At-Home Testing Empowers Consumers and Rapidly Expands the Diagnostic Device Market A fundamental paradigm shift toward patient-centric care, emphasizing convenience, privacy, and empowerment, is fueling explosive growth in the at-home testing sector. This consumer-driven movement represents a critical expansion corridor for the diagnostic segment of the gynecological devices market. The market size reflects this rapid adoption; the global at-home testing market is estimated to reach a value of US$7,789.1 million in 2025, a healthy increase from its US$7,432.3 million valuation in 2024. The fertility testing sub-market is a particularly strong contributor to this growth, and it is estimated to be valued at US$672.9 million in 2025. Long-term projections are even more bullish, with the global Ovulation Test Market projected to expand to US$4.04 billion by 2032. Similarly, the broader global Fertility Testing Devices Market, which was valued at US$702.59 million in 2023, is projected to surge to an impressive US$1,171.55 million by 2032. The distribution channels for these devices are also modernizing to meet consumer demand. The online pharmacy segment has emerged as the dominant channel, holding the largest share of the fertility testing devices market in 2023 at 41.12%. This trend opens up a powerful direct-to-consumer channel, reshaping marketing and logistics for the entire gynecological devices market. Core Surgical and Diagnostic Device Advancements Enhance Overall Patient Care Efficacy Relentless and continuous innovation in the design and function of core surgical and diagnostic instruments remains a fundamental pillar of growth for the gynecological devices market. These advancements directly translate into improved clinical efficacy, enhanced safety profiles, and better patient experiences. A landmark development occurred in 2025 when Kephera Diagnostics launched its EndomTest, which stands as the first commercially available non-invasive blood test for endometriosis in the United States. This represents a significant leap forward in diagnostics. Simultaneously, the regulatory environment is adapting to support and safeguard this innovation. In November 2024, the Food and Drug Administration (FDA) announced a new communications pilot program specifically designed to enhance the medical device recall process, a program that explicitly includes obstetrics and gynecology devices. This heightened focus on safety is critical, as evidenced by an April 2024 recall of Boston Scientific's Obsidio Embolic device. A comprehensive review of high-risk recalls from 2002 through 2016 identified 7 distinct class I recall events that affected over 88,000 women's health medical devices. This history informs the current proactive regulatory stance, which ultimately fosters greater trust and ensures the long-term, sustainable health of the gynecological devices market. Tailor This Report to Your Specific Business Needs: The Staggering Economic Burden of Gynecological Conditions Underscores Urgent Device Need The immense economic weight imposed by common gynecological conditions on healthcare systems, employers, and patients provides a powerful and persuasive argument for the value proposition of effective and cost-efficient medical devices. The annual economic burden of uterine fibroids in the U.S. is a clear example, estimated to be as high as US$41.4 billion. A major driver of this staggering cost is the impact on workforce productivity, with lost wages due to fibroids costing American women approximately US$17.2 billion every year. The economic drain extends beyond fibroids. The annual surgical costs in the U.S. for treating pelvic organ prolapse now exceed US$1.523 billion. These multi-billion-dollar figures create a compelling business case for payers and healthcare providers to aggressively invest in advanced gynecological devices. Devices that can reduce the need for expensive surgeries, shorten hospital stays, minimize recovery times, and mitigate long-term complications offer a clear and quantifiable return on investment. This powerful economic reality serves as a persistent and significant demand driver for the entire gynecological devices market. Global Gynecological Devices Market Major Players: Karl Storz SE & Co. KG Hologic Inc. Boston Scientific Corporation B. Braun Melsungen AG Becton, Dickinson and Company CONMED Corporation CooperSurgical Inc. Coloplast A/S Johnson & Johnson (Ethicon) Medtronic plc Olympus Corporation Stryker Corporation Richard Wolf GmbH Intuitive Surgical Teleflex Incorporated Minerva Surgical Inc. Lumenis Ltd. Other Prominent Players Market Segmentation: By Product Surgical Devices Gynecological Imaging Devices Portable Tools By End Use Hospital & Clinics Ambulatory Surgery Centers (ASCs) By Region North America Europe Asia Pacific Middle East Africa South America Explore the Report Before You Buy – Book a Walkthrough: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
Yahoo
an hour ago
- Yahoo
United States Mint Begins Shipping 2025 American Women Quarters™ Honoring Stacey Park Milbern on August 11
WASHINGTON, D.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- The United States Mint (Mint) will begin shipping the 2025 American Women Quarters (AWQ) Program coin honoring Stacey Park Milbern on August 11, the fourth in this series for 2025. The Mint facilities at Philadelphia and Denver manufacture these circulating quarters. Stacey Park Milbern was a visionary leader and powerful activist for disability justice. Born with physical disabilities, her life experiences led her to inspire and empower others, championing the belief that everyone is inherently valuable. 'The fourth coin of the 2025 American Women Quarters Program celebrates the life and legacy of Stacey Park Milbern,' said United States Mint Acting Director Kristie McNally. 'As a pioneer for disability justice, she empowered and revitalized others. We hope this design reflects her youth, purpose and compassion.' The reverse (tails) design depicts Milbern speaking to an audience. She places one hand near her trach while her right hand faces palm up, in a gesture meant to evoke a genuine exchange of ideas and the building of allyship. The additional inscriptions are 'UNITED STATES OF AMERICA,' 'E PLURIBUS UNUM,' 'QUARTER DOLLAR,' 'DISABILITY JUSTICE,' and 'STACEY PARK MILBERN.' Artistic Infusion Program Designer Elana Hagler designed the reverse image, which Mint Medallic Artist Craig A. Campbell sculpted. 'Stacey Park Milbern's story is one of courage, empathy, and conviction,' said Hagler. 'These are the qualities I tried to capture when I designed her likeness, as well as the duality of her fierceness and gentleness. I am thrilled to do my part get her story out, and I am deeply moved by the thought that people can see aspects of themselves reflected on this quarter, and find encouragement and inspiration in the life and work of Stacey Park Milbern.' 'The joy and honor of celebrating Stacey Park Milbern on this coin far outweigh the challenges faced,' said Campbell. 'It's wonderful to do my part in creating this monument to her memory and legacy. This coin will inspire us and future generations.' Each coin in this series features a common obverse (heads) design depicting a portrait of George Washington. This design was originally composed and sculpted by Laura Gardin Fraser as a candidate entry for the 1932 quarter, which honored the bicentennial of George Washington's birth. The inscriptions are 'LIBERTY,' 'IN GOD WE TRUST,' and '2025.' View an image of the Stacey Park Milbern quarter reverse here. Each 2025 AWQ honoree is a powerful, inspiring example of the breadth, depth, and range of accomplishments, and the experiences demonstrated by these extraordinary women. The fifth and final coin in this series will ship later this year. Authorized by Public Law 116-330, the American Women Quarters Program features coins with reverse (tails) designs emblematic of the accomplishments and contributions of American women. Beginning in 2022 and continuing through 2025, the Mint is issuing five quarters in each of these years. The ethnically, racially, and geographically diverse group of individuals honored through this program reflects a wide range of accomplishments and fields, including suffrage, civil rights, abolition, government, humanities, science, space, and the arts. Please visit as your primary source of the most current information on product and service status or call 1-800-USA-MINT (872-6468) seven days a week from 8 a.m. to 9 p.m. ET. Hearing and speech impaired customers with TTY equipment may order by calling 1-888-321-MINT (6468) Monday through Friday, 8:30 a.m. to 5 p.m. ET. From outside the United States, customers can call 001-202-898-6468 Monday through Friday, 8:30 a.m. to 5 p.m. ET. About the United States Mint Congress created the Mint in 1792, and the Mint became part of the Department of the Treasury in 1873. As the Nation's sole manufacturer of legal tender coinage, the Mint is responsible for producing circulating coinage for the Nation to conduct its trade and commerce. The Mint also produces numismatic products, including proof, uncirculated, and commemorative coins; Congressional Gold Medals; silver and bronze medals; and silver and gold bullion coins. Its numismatic programs are self-sustaining and operate at no cost to taxpayers. ADDITIONAL RESOURCES: Information about the United States Mint. Sign up to receive Mint electronic product notifications, news releases, public statements, and our monthly educational newsletter, Lessons That Make Cents. Visit and subscribe to the Mint's YouTube channel to view videos about the Mint. Follow us on Facebook, X, and Instagram. CONTACT: Sharon McPike United States Mint 202-354-7222 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
